viewProvectus Pharmaceuticals

Provectus notes PV-10 research data release

It is researching PV-10 in melanoma, breast cancer and cancers of the liver

PV-10 is a treatment designed to be injected into solid tumours

Cancer and dermatology specialist Provectus Biopharmaceuticals (NYSE:PVCT) highlighted data has been released on the immunology effects of its PV-10 treatment in colon cancer cells.

PV-10 is a treatment designed to be injected into solid tumours, particularly in melanoma, breast cancer and cancers of the liver, lowering the risk of potential side effects.

The research note - PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells – was presented at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

The presentation, made by Dr Kunda from the University of Illinois, noted that in vitro testing of PV-10 on colon cancer showed it was toxic to the cancerous cells.

Dr Eric Wachter, chief technological officer of Provectus, said: “The work reported in Dr. Kunda’s presentation further expands our understanding of the mechanism of action of PV-10 as an ablative immunotherapy for solid tumors, and parallels immunologic signaling noted upon ablation of melanoma with PV-10.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

12 hours, 8 minutes ago

2 min read